Hydrogen Therapy Helps Lupus Patient Cut Immunosuppressants and Stay in Remission
- Authors
- Hong-Jie Lin, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu
- Journal
- In Vivo
- Year
- 2026
- DOI
- 10.21873/invivo.14411
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Systemic Lupus Erythematosus
- Body System
- Immune System
TL;DR
Hydrogen capsules accompanied sustained lupus remission and major immunosuppressant reduction in one patient, but causation cannot be established.
Key Finding
A single patient with active systemic lupus erythematosus experienced sustained disease remission and was able to discontinue or significantly reduce immunosuppressive medications after adding molecular hydrogen therapy as an adjunct treatment, with improvements maintained over approximately three years of follow-up.
Summary
This case report describes a single patient with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues, who was taking high doses of immune-suppressing medications. When doctors tried to reduce her medications, her disease flared up significantly. After she started taking oral hydrogen capsules as an additional treatment, her disease markers improved dramatically, allowing doctors to reduce and eventually stop most of her medications over about three years while keeping her disease under control. Blood tests showed improvements in disease markers and immune system changes.
Practical Takeaway
While this case report suggests molecular hydrogen may have helped one patient with lupus reduce medication burden, it describes only a single patient's experience and is not proof that hydrogen water would work for others. Controlled clinical trials involving larger groups of patients are needed before any conclusions can be drawn about hydrogen's effectiveness for lupus or other autoimmune conditions. Anyone with lupus should discuss any new treatments with their rheumatologist before making changes.
Abstract
Background/aim: Management of systemic lupus erythematosus (SLE) remains challenging: intensive immunosuppression increases infection risk, whereas dose reduction may trigger disease flares. Molecular hydrogen (H2), a selective antioxidant with anti-inflammatory properties, may serve as an adjunct therapy, potentially maintaining disease control while reducing immunosuppressive burden. Case report: We present a 43-year-old female with longstanding SLE who experienced recurrent hospitalized infections (pneumonia and complex urinary tract infections) under high-dose immunosuppression in 2022. A subsequent attempt to reduce her medication dosage provoked a significant disease flare in January 2023, with anti-double stranded DNA (anti-dsDNA) levels surging to 890 IU/ml and complement depletion. Oral H2 capsule therapy was initiated as an adjunct. The patient exhibited rapid and robust serologic improvement, allowing for the complete discontinuation of mycophenolic acid within one month. Over an extended follow-up through early 2026, her regimen was successfully de-escalated to a minimized monotherapy of prednisolone 10 mg/day. Her anti-dsDNA levels stabilized within a strictly normal range (<15 IU/ml), with normalized complement levels, no further infections, and profoundly reduced fatigue. Flow-cytometric profiling revealed a coordinated reprogramming of adaptive immunity toward a controlled, non-senescent state, including a homeostatic reset in the B-cell compartment and decreased active-disease-associated T cells. Conclusion: Adjuvant molecular hydrogen therapy stabilized active SLE, enabling substantial reduction of conventional immunosuppressants while maintaining durable clinical and serologic remission. This strategy may represent a promising immunosuppressant-sparing approach and warrants validation in controlled trials.